RASSF1 and lung cancer: Combining SHOX2 and RASSF1A, the specificity and sensitivity of LungMe® were 90.0 and 89.3% in the training set and were 90.7 and 90.3% in the validation set, indicating that SHOX2 and RASSF1A gene methylation as lung cancer biomarker panel has excellent accuracy for lung cancer diagnosis (data were shown in Supplementary Table 2).